## **DVT Prophylaxis for COVID-19 Patients – JHH MICU (Sickest Patients)**

- Recommending more aggressive VTE prophylaxis in patients with ARDS who are <a href="heavily sedated">heavily sedated</a> and at high risk of DVT/PE
- > Patients can be transitioned to usual prophylaxis \*\* once recovered from ARDS/perceived to be lower clot risk

Creatinine Clearance or other modifier	Recorded weight 40-70 kg*	Recorded weight 71-119 kg	Recorded weight > 120 kg
ARDS with CrCL ≥30 mL/min	Heparin 5000 units q 8 h	Enoxaparin 30 mg q 12 h	Enoxaparin 40 mg q 12 h
<ul> <li>ARDS with CrCl         &lt; 30 mL/min</li> <li>Increased concern         for bleeding</li> <li>Patients no longer         deemed highest         clot risk</li> </ul>	Heparin 5000 units q 8 h	Heparin 5000 units q 8 h	Heparin 7500 units q 8 h

<sup>\*</sup>For patients < 40 kg, consider use of lower dose (ex q 12 hr); "recorded weight" = wt on day of order \*\* usual prophylaxis = heparin 5000 units q 8 or enoxaparin 40 q 24 hrs; adjusted for size and/or renal function

3/25/2020 - A. Rowden, PharmD

## VTE Prophylaxis for Non-ICU COVID Positive Patients (Not quite as sick)

If very high risk and confirmed COVID +, start high intensity VTE prophylaxis (**Table 1**); very high risk characteristics include:

- Pregnancy
- Active malignancy
- Prior VTE
- Sickle cell disease

For other confirmed COVID + patients not meeting very high risk for VTE criteria above, start standard VTE prophylaxis (**Table 2**). With next set of labs and daily thereafter, obtain CBC, fibrinogen, D-dimer, factor VIII activity.\* If <u>any</u> of the following lab parameters are met, escalate to appropriate high-intensity dosing strategy (**Table 1**):

- Fibrinogen > 500 mg/dL
- D-dimer > 2 mg/L
- Factor VIII activity > 250 IU/dL
- Platelet count > 350,000/μL

**Table 1: High-Intensity VTE Prophylaxis Dosing** (all via subcutaneous route)

Renal Function	Actual body weight	Actual body weight	Actual body weight > 120 kg
	40-59 kg	60-119 kg	(or BMI > 40 kg/m <sup>2</sup> )
CrCl > 30 mL/min	UFH 5,000 units q8h**	Enoxaparin 30 mg	Enoxaparin 40 mg BID
		BID	
CrCl < 30 mL/min	UFH 5,000 units q8h**	UFH 7,500 units q8h	UFH 10,000 units q8h**

<sup>\*\*</sup> Consider checking aPTT daily (timed with other labs/medication administration to reduce to assess for accumulation; if aPTT > 40 seconds, consider dose reduction (to 5,000 q12h from 5,000 q8h or to 7,500 q8h from 10,000 q8h)

**Table 2: Standard VTE Prophylaxis Dosing** (all via subcutaneous route)

	1 /	· · · · · · · · · · · · · · · · · · ·	
Renal Function	Actual body weight	Actual body weight 60-	Actual body weight > 120 kg
	40-59 kg	119 kg	(and/or BMI > 40 kg/m²)
CrCl ≥ 30 mL/min	UFH 5,000 units q12h	Enoxaparin 40 mg daily	Enoxaparin 40 mg BID
CrCl < 30 mL/min	UFH 5,000 units q12h	UFH 5,000 units q8h	UFH 7,500 units q8h

<sup>\*</sup>Lab timing should be coordinated to occur when other routine labs are due and/or medication administration is necessary. Obtainment of these labs should not require an extra trip into the patient's room and use of additional PPE.